A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study):

Ryota Shibaki,Hiroaki Akamatsu,Terufumi Kato,Kazumi Nishino,Morihito Okada,Tetsuya Mitsudomi,Kazushige Wakuda,Kenichi Yoshimura,Nobuyuki Yamamoto,Kazuhiko Nakagawa

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study):

2021

Ryota Shibaki
Hiroaki Akamatsu
Terufumi Kato
Kazumi Nishino
Morihito Okada
Tetsuya Mitsudomi
Kazushige Wakuda
Kenichi Yoshimura
Nobuyuki Yamamoto
Kazuhiko Nakagawa

Background:Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is a standard treatment in EGFR-mutated advanced non-small-cell lung cancer (NSCLC); however, previous data have s...

Keywords:

Oncology
Lung cancer
Standard treatment
Vinorelbine
Atezolizumab
Cisplatin
Internal medicine
Epidermal growth factor receptor
Medicine
Adjuvant therapy
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations